In conclusion, we propose that KLK1, KLK2, KLK3 KLK4, KLK8, KLK9, and KLK14, which are differentially expressed in prostate cancer, could be used as promising biomarkers of prostate cancer progression. This evidence concerns the gene KLK2 and Familial prostate cancer.